Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H1 2016

Publication ID: GMD0516134
Publication Date: May 31, 2016
Pages: 55
Publisher: Global Markets Direct
Countries: Global [1]

$3,500.00

Publication License Type *

- SINGLE USER LICENSE (PDF), $3,500.00
- SITE LICENSE (PDF), $7,000.00
- GLOBAL LICENSE (PDF), $10,500.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.
Description:

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Interleukin-2 Receptor Subunit Alpha (IL-2 Receptor Subunit Alpha or TAC Antigen or p55 or CD25) - Pipeline Review, H1 2016’, provides in depth analysis on Interleukin-2 Receptor Subunit Alpha (IL-2 Receptor Subunit Alpha or TAC Antigen or p55 or CD25) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin-2 Receptor Subunit Alpha (IL-2 Receptor Subunit Alpha or TAC Antigen or p55 or CD25), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin-2 Receptor Subunit Alpha (IL-2 Receptor Subunit Alpha or TAC Antigen or p55 or CD25) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin-2 Receptor Subunit Alpha (IL-2 Receptor Subunit Alpha or TAC Antigen or p55 or CD25)
- The report reviews Interleukin-2 Receptor Subunit Alpha (IL-2 Receptor Subunit Alpha or TAC Antigen or p55 or CD25) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin-2 Receptor Subunit Alpha (IL-2 Receptor Subunit Alpha or TAC Antigen or p55 or CD25) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin-2 Receptor Subunit Alpha (IL-2 Receptor Subunit Alpha or TAC Antigen or p55 or CD25) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin-2 Receptor Subunit Alpha (IL-2 Receptor Subunit Alpha or TAC Antigen or p55 or CD25) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin-2 Receptor Subunit Alpha (IL-2 Receptor Subunit Alpha or TAC Antigen or p55 or CD25)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin-2 Receptor Subunit Alpha (IL-2 Receptor Subunit Alpha or TAC Antigen or p55 or CD25) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

**Table Of Contents:**

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Overview 6
Therapeutics Development 7
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Products under Development by Stage of Development 7
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Products under Development by Therapy Area 8
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Products under Development by Indication 9
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Products under Development by Companies 12
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Companies Involved in Therapeutics Development 21
AbbVie Inc. 21
Alkermes Plc 22
APT Therapeutics, Inc. 23
Oct 08, 2015: Results from ZINBRYTA (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECTRIMS 44

Oct 01, 2015: Biogen To Present Phase 3 Data On ZINBRYTA at ECTRIMS Congress 46

Apr 29, 2015: FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS 47

Apr 13, 2015: Alkermes to Present Preclinical Data on Novel Selective Effector Cell Activator Immuno-Oncology Candidate at Upcoming American Association for Cancer Research Annual Meeting 48

Mar 27, 2015: European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA (Daclizumab High-Yield Process) for Treatment of MS 48

Feb 26, 2015: Abbvie's Ongoing Research In Neuroscience And Oncology On ZINBRYTA Will Be Featured At The 2015 American Academy Of Neurology Annual Meeting 49

Sep 12, 2014: Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA (Daclizumab High-Yield Process) 50

Jun 16, 2014: Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis 52

May 29, 2014: Philogen reports objective responses and striking efficacy in clinical trials of Darleukin in advanced metastatic melanoma 53

Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55
Pipeline by AbbVie Inc., H1 2016 21
Pipeline by Alkermes Plc, H1 2016 22
Pipeline by APT Therapeutics, Inc., H1 2016 23
Pipeline by Mabtech Limited, H1 2016 24
Pipeline by Philogen S.p.A., H1 2016 25
Dormant Projects, H1 2016 37
Dormant Projects (Contd.), H1 2016 38

List of Figures
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Top 10 Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Mechanism of Actions, H1 2016 15
Number of Products by Stage and Mechanism of Actions, H1 2016 15
Number of Products by Routes of Administration, H1 2016 17
Number of Products by Stage and Routes of Administration, H1 2016 17
Number of Products by Molecule Types, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 19

Companies Mentioned:
AbbVie Inc.
Alkermes Plc
APT Therapeutics, Inc.
Mabtech Limited
Philogen S.p.A.

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

**Site License (PDF)**

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

**Global License (PDF)**

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

---

**Source URL:** https://www.marketresearchreports.com/global-markets-direct/interleukin-2-receptor-subunit-alpha-tac-antigen-or-p55-or-cd25-or-il2ra

**Links**